Longitudinal databases can have several advantages for pharma companies in comparison to collecting data from clinical trials alone.
In December 2018, FDA Commissioner Scott Gottlieb, MD, issued a statement about how real-world data (RWD) and real-world evidence (RWE) offer opportunities to understand clinical outcomes of pharmaceutical products. RWD comes from a variety of sources, including EHRs, medical claims, lab results, and wearable and home monitoring devices, such as glucometers and oximeters. “Because they include data covering the experience of physicians and patients with the actual use of new treatments in practice, and not just in research studies, the collective evaluation of these data sources has the potential to inform clinical decision making by patients and providers, develop new hypotheses for further testing of new products to drive continued innovation, and inform us about the performance of medical products,” the statement reads.
A longitudinal database is a collection of de-identified RWD and RWE from many patients over many years, which can have several advantages for pharma companies, versus data collected from clinical trials alone. Some uses for a longitudinal database in the pharmaceutical sector include:
What this means for pharma companies is that the results they get in clinical trials may not be an accurate representation of the results they will see once a drug comes to market. However, a longitudinal database can provide pharma companies with many years of RWD and RWE from thousands of patients. Analyzing such information can show adverse effects and overall efficacy in ways that clinical trials of a few months or even a few years cannot.
Seeing these trends, over time, can inform the pharmaceutical industry about which molecules, mechanisms of action, and therapies result in better patient outcomes. This information can help pharma companies focus and narrow their R&D efforts, shaving off billions of dollars and several years in the process of getting new drugs to market. It can also help pharmaceutical sales reps target their marketing efforts, sharing data on certain medications with certain doctors based on the physicians’ target populations, or offering statistics about which medications historically show the best outcomes.
In its December statement, the FDA recognized the value that RWD and RWE can have on such postmarketing studies. Longitudinal databases of such RWD over time can be even more valuable in this context. “Traditional post-market studies typically require years to design and complete and cost millions of dollars. By using RWD and RWE, we may be able to provide patients and providers with important answers sooner-identifying a broader range of safety signals and following up on them more efficiently,” the FDA statement says.
In addition, the FDA says it is also using RWD and RWE as part of the information it takes into consideration when evaluating new drug applications (NDAs) from pharma companies. “We currently have new drug applications under review where RWD and RWE are helping to inform our ongoing evaluation as one component of the total complement of information that we’re evaluating,” the organization says.
William T. Sander, PharmD, is chief revenue officer of Sentry Data Systems.
From Potential to Value: Carving a Slice of the CGT ‘PIE'
August 15th 2024The importance of pre-approval information exchange (PIE) with payers and other strategic considerations to help navigate today’s market access challenges and regulatory requirements in bringing promising cell and gene therapies to the market.
Pharm Exec Exclusive: Mark Cuban Talks Drug Pricing
June 7th 2024Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur, in an interview with Pharm Exec, discusses the prescription drug cost landscape and shares his recipe for true disruption to the pharma pricing machine.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.